Q3 EPS Estimates for Zimmer Biomet Boosted by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Zacks Research raised their Q3 2026 earnings per share estimates for shares of Zimmer Biomet in a note issued to investors on Monday, June 16th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.02 per share for the quarter, up from their previous estimate of $2.00. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share.

ZBH has been the topic of a number of other research reports. Truist Financial set a $101.00 target price on Zimmer Biomet in a research note on Tuesday, May 6th. Raymond James Financial dropped their price target on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird dropped their price target on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group dropped their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Trading Up 0.7%

ZBH stock traded up $0.67 during midday trading on Thursday, reaching $91.22. The company's stock had a trading volume of 4,060,771 shares, compared to its average volume of 1,802,564. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. The stock has a fifty day simple moving average of $95.28 and a two-hundred day simple moving average of $102.85. Zimmer Biomet has a 1 year low of $89.22 and a 1 year high of $116.71. The firm has a market capitalization of $18.05 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 2.09 and a beta of 0.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter last year, the firm posted $1.94 earnings per share. The business's revenue was up 1.1% compared to the same quarter last year.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the business. Dorsey & Whitney Trust CO LLC raised its stake in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after purchasing an additional 102 shares during the last quarter. M&T Bank Corp raised its stake in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after purchasing an additional 108 shares during the last quarter. MGO One Seven LLC raised its stake in shares of Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 110 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock worth $2,903,000 after purchasing an additional 118 shares during the last quarter. Finally, FWG Holdings LLC raised its stake in shares of Zimmer Biomet by 3.5% in the fourth quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider's stock worth $402,000 after purchasing an additional 124 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider now owns 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.05%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.